Acuitas co-founder Pieter Cullis on breakthrough vaccine innovation

A made-in-B.C. innovation is playing a critical role in the Pfizer-BioNTech COVID-19 vaccine rolling out across the globe. Lipid nanoparticle technology — or LNP — developed by Vancouver’s Acuitas Therapeutics is one of the key factors allowing the vaccine to work. Acuitas co-founder Pieter Cullis joins BIV Today to break it down. Tyler Orton hosts.See omnystudio.com/listener for privacy information.